Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

By C. Legendre, C. Licht, P. Muus, Lawrence Greenbaum, S. Babu, C. Bedrosian, C. Bingham, D. Cohen, Yahsou Delmas, K. Douglas and 23 more. New England Journal of Medicine, 2013

1,437 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Nephrology

View Paper: https://www.semanticscholar.org/paper/1bd7125f3791004e773a78ee119a598739b08ed9

Citations in the corpus

• Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. (2017, neutral): “The dosing schedule reported in the trials is recommended, although 2 options for altered dosing have been considered: (i) the minimal dose required to achieve complement blockade; and (ii) a discontinuation dosing schedule.(79) No data exist to support either option, and both require monitoring of ”